Psyence Biomedical (PBM) FDA Approvals $3.69 -0.26 (-6.58%) Closing price 04:00 PM EasternExtended Trading$3.73 +0.04 (+1.08%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Psyence Biomedical's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Psyence Biomedical (PBM). Over the past two years, Psyence Biomedical has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as NPX-5. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. NPX-5 FDA Regulatory Events NPX-5 is a drug developed by Psyence Biomedical for the following indication: for Adjustment Disorder. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Dosing Update - April 23,2026Dosing Update Phase 2bDrug: NPX-5Announced Date: April 23, 2026Indication: for Adjustment DisorderAnnouncementPsyence Biomedical Ltd. announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting.AI SummaryPsyence Biomedical Ltd. announced the first patient has been dosed in its Phase IIb clinical trial of NPX-5 (25 mg nature-derived psilocybin) for Adjustment Disorder in patients with cancer receiving palliative care. This marks the company’s first large-scale human evaluation of NPX-5 and the start of systematic data generation across five Australian clinical sites, including centers in Perth and Melbourne. NPX-5 is described as a GMP-compliant, nature-derived psilocybin developed through PsyLabs as part of Psyence’s vertically integrated platform. The randomized, double-blind, three-arm trial will assess safety, tolerability, clinical response, and treatment durability when psilocybin is given alongside structured therapeutic support. The study’s results are intended to inform future development and potential regulatory pathways. Dr. Neil Maresky said the team is focused on disciplined execution, consistent patient recruitment, and producing high-quality data to evaluate the therapeutic potential of a 25 mg dose.Read Announcement Psyence Biomedical FDA Events - Frequently Asked Questions Has Psyence Biomedical received FDA approval? As of now, Psyence Biomedical (PBM) has not received any FDA approvals for its therapy in the last two years. What drugs has Psyence Biomedical submitted to the FDA? In the past two years, Psyence Biomedical (PBM) has reported FDA regulatory activity for NPX-5. What is the most recent FDA event for Psyence Biomedical? The most recent FDA-related event for Psyence Biomedical occurred on April 23, 2026, involving NPX-5. The update was categorized as "Dosing Update," with the company reporting: "Psyence Biomedical Ltd. announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting." What conditions do Psyence Biomedical's current drugs treat? Currently, Psyence Biomedical has one therapy (NPX-5) targeting the following condition: for Adjustment Disorder. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Axsome Therapeutics FDA EventsBiogen FDA EventsFate Therapeutics FDA EventsGH Research FDA EventsIncyte FDA EventsJazz Pharmaceuticals FDA EventsMoleculin Biotech FDA EventsMirum Pharmaceuticals FDA EventsNextCure FDA EventsPharming Group FDA EventsRegeneron Pharmaceuticals FDA Eventsargenex FDA EventsCabaletta Bio FDA EventsDyne Therapeutics FDA EventsFibroBiologics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Traws Pharma FDA Events BioLineRx FDA Events Cocrystal Pharma FDA Events HOOKIPA Pharma FDA Events CytoMed Therapeutics FDA Events Jasper Therapeutics FDA Events Moleculin Biotech FDA Events Phio Pharmaceuticals FDA Events BioVie FDA Events Chemomab Therapeutics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:PBM last updated on 4/23/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredA New Approach to Affordable Housing75% of U.S. households cannot afford a median-priced new home. BOXABL's factory-built, foldable homes are desi...BOXABL | SponsoredTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | SponsoredMusk is burning $2.5 billion a quarter on AI. One company holds the key.SpaceX's S-1 filing reveals $7.7 billion spent on AI infrastructure in a single quarter - not chips, not softw...Behind the Markets | SponsoredGiving “2022 pre-ChatGPT” vibes (but 10x bigger)When ChatGPT launched in 2022, Nvidia surged 1,800% over three years. Now, Nvidia's CEO suggests July 22nd cou...StocksToTrade | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psyence Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Dosing Update - April 23,2026Dosing Update Phase 2bDrug: NPX-5Announced Date: April 23, 2026Indication: for Adjustment DisorderAnnouncementPsyence Biomedical Ltd. announced that the first patient has been dosed in its Phase IIb clinical trial evaluating NPX-5 (25mg of nature-derived psilocybin) for the treatment of Adjustment Disorder in patients with cancer in a palliative care setting.AI SummaryPsyence Biomedical Ltd. announced the first patient has been dosed in its Phase IIb clinical trial of NPX-5 (25 mg nature-derived psilocybin) for Adjustment Disorder in patients with cancer receiving palliative care. This marks the company’s first large-scale human evaluation of NPX-5 and the start of systematic data generation across five Australian clinical sites, including centers in Perth and Melbourne. NPX-5 is described as a GMP-compliant, nature-derived psilocybin developed through PsyLabs as part of Psyence’s vertically integrated platform. The randomized, double-blind, three-arm trial will assess safety, tolerability, clinical response, and treatment durability when psilocybin is given alongside structured therapeutic support. The study’s results are intended to inform future development and potential regulatory pathways. Dr. Neil Maresky said the team is focused on disciplined execution, consistent patient recruitment, and producing high-quality data to evaluate the therapeutic potential of a 25 mg dose.Read Announcement
